Where is Incyte Corporation (INCY) Headed According to Analysts?

Incyte Corporation (NASDAQ:INCY) is one of the best immunotherapy stocks to buy according to hedge funds. Jefferies reiterated a Buy rating on Incyte Corporation (NASDAQ:INCY) on February 11, setting a price target of $120. The same day, Morgan Stanley also lifted the price target on the stock to $102 from $94 while maintaining an Equal Weight rating on the shares. Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds is Buying Incyte Corporation (NASDAQ:INCY) also received a bullish r ...